A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

NCT01644500 · Completed

Last updated 2026-05-28

This clinical trial compares the effects and safety of dulaglutide versus glimepiride in adults with type 2 diabetes over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 737 people

Who can join Ages 18+ · all sexes

Timeline Started 2012-07 · est. completion 2014-08

Where 30 sites · China, South Korea, Taiwan

What this study is testing ClinicalTrials.gov NCT01644500 ↗

Description as written by the study sponsor.

The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate glycemic control with oral antihyperglycemic medication (OAM) or are OAM-naïve.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC
Glimepiride Drug

Administered orally
Placebo as Capsules Drug

Placebo for glimepiride is administered orally as one to three capsules daily.
Placebo as SC Injection Drug

Placebo for dulaglutide is administered as one SC injection.

Main thing measured	Change From Baseline in HbA1c at 26 Weeks
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01644500 ↗